
Sign up to save your podcasts
Or
Earlier this year, Profluent announced it had edited the human genome with OpenCRISPR-1, the world’s first AI-created and open-source gene editor. Though the open-source aspect helped garner attention for Profluent, it also served as a demonstration of the company’s generative AI platform to create novel CRISPR gene editors. We spoke to Hilary Eaton, chief business officer for Profluent, about how the company’s generative AI engine works, its business model, and why its platform has the potential to create other protein therapeutics of varying modalities.
3.7
3939 ratings
Earlier this year, Profluent announced it had edited the human genome with OpenCRISPR-1, the world’s first AI-created and open-source gene editor. Though the open-source aspect helped garner attention for Profluent, it also served as a demonstration of the company’s generative AI platform to create novel CRISPR gene editors. We spoke to Hilary Eaton, chief business officer for Profluent, about how the company’s generative AI engine works, its business model, and why its platform has the potential to create other protein therapeutics of varying modalities.
4,169 Listeners
1,707 Listeners
3,383 Listeners
2,173 Listeners
1,450 Listeners
9,529 Listeners
325 Listeners
7,033 Listeners
6,055 Listeners
33 Listeners
488 Listeners
5,472 Listeners
20 Listeners
48 Listeners
383 Listeners